 
Study Title  
The effect of Cranial Laser Reflex Technique on hamstring function: a pi[INVESTIGATOR_883716] : 03044106   
 
Document Date : Jan 25, [ADDRESS_1236385] OF CRANIAL LASER REFLEX TECHNIQUE ON 
HAMSTRING FLEXIBILITY , STRENGTH AND PAIN 
PRESSURE THRESHOLD : A PI[INVESTIGATOR_883717] 1 of 62 version 1.1  
January 25, 2017    
 
 PROTOCOL  
Title: The Effects of Cranial Laser Reflex Technique (CLRT) on Ha mstring Flexibility, 
Strength and Pain Pressure Threshold: a pi[INVESTIGATOR_804993]:   
Nicholas A. Wise, D.C.   
T32 Postdoctoral Research Fellow  
University of North Carolina Program on Integrative Medicine  
Department of Physical Medicine and Rehabilitation, Chapel Hill, NC    
  
Supported by:  
[CONTACT_883741]  T32 Fellowship  
 
  
Sponsor of IND (IDE):   
None Required   
 
Master Protocol CLRT for Hamstrings  Page 2 of 62 version 1.1  
January 25, 2017    
 
 TOOL REVISION HISTORY  
Version Number: 1. 1 
Version Date: January 25, 2017  
Master Protocol CLRT for Hamstrings  Page 3 of 62 version 1.1  
January 25, 2017    
 
  
Table of C ontents  
PROTOCOL  ............................................................................................................................................... 1  
TOOL REVISION HISTORY  .......................................................................................................................... 2  
Version Number: 1.1  ...............................................................................................................................................2  
STUDY TEAM ROSTER  ............................................................................................................................... 7  
Principal In vestigator ...............................................................................................................................................7  
Co-Investigators  .......................................................................................................................................................7  
Biostatistic ian...........................................................................................................................................................7  
Study Coordinators  ................................................................................................. Error! Bookmark not defined.  
Research Assistants  .................................................................................................................................................[ADDRESS_1236386] OF ABBREVIATIONS  ........................................................................................................................... 9  
2. BACKGROUND AND RATIONALE  .......................................................................................................... 10 
2.1: Background  .................................................................................................................................................... 10 
2.2: Study Rationale  ............................................................................................................................................. 11 
3. STUDY DESIGN  ................................................................................................................................... 11 
4. SELECTION  AND ENROLLMENT OF PARTICIPANTS  ................................................................................ 14 
4.1: Inclusion Criteria  ........................................................................................................................................... 14 
4.2: Exclusion Criteria  ........................................................................................................................................... 14 
4.3: Study Enrollment Procedures ....................................................................................................................... 15 
5. STUDY INTERVENTION  ........................................................................................................................ 16 
5.1: Intervention, Administration, and Duration  ............................................................................................... 16 
Master Protocol CLRT for Hamstrings  Page 4 of 62 version 1.1  
January 25, 2017    
 
 5.2: Concomitant Interventions ........................................................................................................................... 16 
5.2.1: Allowed Interventions ........................................................................................................................... 16 
5.2.2: Required Interventions  ......................................................................................................................... 17 
5.2.3: Prohibited Interventions ....................................................................................................................... 17 
5.3: Adherence Assessment ................................................................................................................................. 17 
6. STUDY PROCEDURES ........................................................................................................................... 17 
6.1: Schedule of Evaluations  ................................................................................................................................ 17 
6.2: Description of Evaluations  ............................................................................................................................ 17 
6.2.1: Screening Evaluation and Consenting  ................................................................................................. 17 
6.2.2: Enrollment, Baseline, and/or Randomization  ..................................................................................... 18 
6.2.3: Blinding  .................................................................................................................................................. 18 
6.2.4: Study Visits  ............................................................................................................................................ 18 
6.2.5: C ompletion  ............................................................................................................................................ 19 
7. SAFETY ASSESSMENTS  ........................................................................................................................ 20 
7.1: Specification of Safety Parameters  .............................................................................................................. 20 
7.2: Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  .................................. 20 
7.3: Adverse Events (AEs) and Serious Adverse Events (SAEs) .......................................................................... 20 
Definitions  ........................................................................................................................................................ 20 
Classifi cation of AE Severity  ............................................................................................................................ 21 
AE Attribution Scale  ......................................................................................................................................... 21 
7.4: Reporting Procedures  ................................................................................................................................... 22 
7.5: Follow up for Adverse Events  ....................................................................................................................... 22 
7.6: Safety Monitoring  ......................................................................................................................................... 22 
8. INTERVENTION DISCONTINUATION  ..................................................................................................... 22 
9. STATISTICAL CONSIDERATIONS  ........................................................................................................... 23 
9.1: General Design Issues  ................................................................................................................................... 23 
9.2: Sample Size and Randomization  .................................................................................................................. 24 
Master Protocol CLRT for Hamstrings  Page 5 of 62 version 1.1  
January 25, 2017    
 
 9.3: Definition of Populations  .............................................................................................................................. 24 
9.4: Interim Analyses and Stoppi[INVESTIGATOR_1869] ........................................................................................................... 24 
9.5: Outcomes ....................................................................................................................................................... 24 
9.5.1: Primary  Outcome  .................................................................................................................................. 24 
9.5.2: Secondary Outcomes  ............................................................................................................................ 24 
9.6: Data Analyses  ................................................................................................................................................ 24 
10. DATA COLLECTION AND QUALITY ASSURANCE  ................................................................................... 25 
10.1: Data Collection Forms:  Data Type & Personnel Collecting Data  ............................................................ 25 
10.2: Data Management  ...................................................................................................................................... 25 
10.3: Quality Assurance  ....................................................................................................................................... 25 
10.3.1: Training  ................................................................................................................................................ 25 
10.3.2: Quality Control Committee  ................................................................................................................ 26 
10.3.3: Metrics  ................................................................................................................................................. 26 
10.3.4: Protocol Deviations  ............................................................................................................................. 26 
10.3.5: Monitoring  ........................................................................................................................................... 27 
11. PARTICIPANT RIGHTS AND CONFIDENTIALITY  .................................................................................... 27 
11.1: Institutional Review Board (IRB) Review  ................................................................................................... 27 
11.2: Informed Consent Forms  ............................................................................................................................ 27 
11.3: Participant Confidentiality .......................................................................................................................... 27 
11.4: Study Discontinuation Understanding ....................................................................................................... 28 
12. COMMITTEES  ................................................................................................................................... 28 
13. PUBLICATION OF RESEARCH FINDINGS  .............................................................................................. 28 
14. REFERENCES  ..................................................................................................................................... 28 
15. SUPPLEMENTS/APPENDICES  ............................................................................................................. [ADDRESS_1236387]  ..................................................................................................................................................... 33 
A. Consent Form  ......................................................................................................................................... 33 
B. Data Coll ection Forms  ............................................................................................................................ 33 
Master Protocol CLRT for Hamstrings  Page 6 of 62 version 1.1  
January 25, 2017    
 
 C.      AE & SAE Forms ....................................................................................................................................... 33 
 
 
Master Protocol CLRT for Hamstrings  Page 7 of 62 version 1.1  
January 25, 2017    
 
 STUDY TEAM ROSTER  
Principal Investigator   
[INVESTIGATOR_883718] , PI, Physical Medicine and Rehabilitation , 183 Wing D, C.B.#7200, [ADDRESS_1236388], UNC School of Medicine, Chapel Hill, N.C.  [ZIP_CODE] -7025.  Phone : 919 -966-8865 , Fax : 919 -
843-5791, e mail : [EMAIL_16805]  
Co-Investigators  
Brian Pi[INVESTIGATOR_98429], Co -I, Department Of Exercise and Sports Science , 26D Fetzer Hall  
University of North Carolina , Chapel Hill, NC [ZIP_CODE] . Phone: (919) 962 -3617, Fax: (919) 962- 0489, 
email: [EMAIL_16806]  
 
Susan Ann Gaylord , Co-I, Department of Physical Medicine and Rehabilitation, 183 Wing D, 
C.B.#7200, [ADDRESS_1236389], UNC School of Medicine, Chapel Hill, N.C.  [ZIP_CODE] -7025. Phone: 
[PHONE_2406], email: [EMAIL_2061]  
Jacob Hill, Co -I Department of Physical Medicine and Rehabilitation, 183 Wing D, C.B.#7200, [ADDRESS_1236390], UNC School of Medicine, Chapel Hill, N.C.  [ZIP_CODE] -7025 
Biostatistic ian 
Mark Weaver, Biostatistician , NC TraCS. 258 Brinkhous -Bullitt Building, CB #7064, Chapel Hill, 
NC [ZIP_CODE]. Phone: (919) 843- 7680, email: [EMAIL_1850]  
 
Research Assistants  
 TBD 
PARTICIPATING STUDY SITES  
Primary Site : EXSS Neurophysiology Lab, Fetzer Hall, University of North Carolina;  Chapel Hill, North 
Carolina, [ZIP_CODE]. 
Secondary Site : UNC Medical School, Wing D. C.B.#7200, [ADDRESS_1236391], UNC School of Medicine, 
Chapel Hill, N.C.  [ZIP_CODE] -7025.  
  
Master Protocol CLRT for Hamstrings  Page 8 of 62 version 1.1  
January 25, 2017    
 
 PR√âCIS  
Title : The Effects of Cranial Laser Reflex Technique ( CLRT) on Hamstring Flexibility,  Strength , and Pain: a 
pi[INVESTIGATOR_799] . 
Objectives : To assess the acute effect on hamstring flexibility, strength , and pain pressure threshold of a 
novel laser therapy intervention  (CLRT)  compared to sham.  
Design and Outcomes  
This is a randomized, blinded crossover trial with 44 healthy young adults that will compare the acute 
effects of CLRT to  sham laser  on hamstring flexibility, strength , and pain pressure threshold (PPT) . The 
primary outcome is hamstring flexibility , which will be assessed by [CONTACT_883742] -Extension -Angle (KEA). As secondary outcomes, hamstring  strength will be measured 
using handheld dynamometry (HHD) , and PPT with digital algometry . The intervention will consist of 
low-level -laser stimulation of the hamstring cranial reflex points for an av erage total treatment time of 
[ADDRESS_1236392] access to 
usual care throughout the research study. The research study will be conducted at the Neurophysiology Lab at the University of North Carolina  and in UNC Medical School, Wing D . 
 
Specific Aim 1: To examine the acute effect of CLRT on hamstring flexibility as measured by [CONTACT_883743] 90 -90 Knee Extension Angle (KEA) test.  
Hypothesis 1:  CLRT will increase mean hamstring flexibility immediately after treatment.  
 
Specific Aim 2: To ex amine  the acute effect of CLRT on hamstring strength as measured by [CONTACT_224695] (HHD) . 
Hypothesis 2 : CLRT will have a neutral to positive effect on hamstring strength.  
 
Specific Aim 3: To examine the acute effect of CLRT on hamstring pain pressure threshold as measured 
by [CONTACT_883744].  
Hypothesis 3:  CLRT will increase  PPT in the hamstrings.  
 
  
 
  
Master Protocol CLRT for Hamstrings  Page [ADDRESS_1236393] OF ABBREVIATIONS  
ADL Activity of Daily Living  
AE Adverse Event/Adverse Experience  
ATP adenosine triphosphate  
CLRT  Cranial Laser Reflex Technique  
Co-I Co-Investigator  
CRF Case Report Form  
CRP Cranial Reflex Point  
CTCAE  Common Terminology Criteria for Adverse Events  
DHHS  Department of Health and Human Services  
DSMC  Data and Safety Monitoring Committee  
EXSS  Exercise and Sport Science  
FDA Food and Drug Administration  
HHD  Handheld Dynamometry  
HIPAA  Health Insurance Portability and Accountability Act  
Hz Hertz  
ICF Informed Consent Form  
IDE Investigational Device Exemption  
IRB Insitutional Review Board  
KEA Knee extension angle  
LLLT  Low level laser therapy  
LTrP  Latent trigger point  
mtNO  mitochondrial nitric oxide  
mW miliwatt  
NC TraCS  North Carolina Translational and Clinical Sciences Institute  
NIH National Institutes of Health  
nm nanometer  
NRS Numerical Rating Scale  
OHRP  Office for Human Research Protections  
PBM  Photobiomodulation  
PI [INVESTIGATOR_883719]/Serious Adverse Experience  
tcPBM  Transcranial Photobiomodulation  
UNC  University of North Carolina  
UNC -CH University of North Carolina at Chapel Hill  
UP Unexpected Problem  
US [LOCATION_002]  
Master Protocol CLRT for Hamstrings  Page 10 of 62 version 1.1  
January 25, 2017    
 
  
2. BACKGROUND AND RATIONALE  
2.1: Background  
Hamstring injuries are a common occurrence in many sports that involve sudden or explosive 
movements , such as jumpi[INVESTIGATOR_883720]. Soccer and lacrosse players are especially at risk for these 
frustrating injuries that have the highest rate of recurrence (12 -31%) in sport s(1) making prevention and 
rehabilitation important areas of study. Static stretching is widely performed , even though it may cause 
a significant loss of strength (2), endurance (3), and explo sive performance for 24 hours (4). Latent 
myofascial trigger points (LTrPs) are typi[INVESTIGATOR_883721] y(5). Currently no clear consensus exists on the most effective protocols for prevention of 
hamstring injuries( 6), but decrea sed flexibility and reduced strength are known risk factors for 
hamstring strain (1) and other m usculoskeletal lesions such as l ower back pain (7). 
 Low Level Laser Therapy (LLLT ) aka  Photobiomodulation (PBM ) is the application of low doses of 
monochromatic coherent light from low powered laser devices to induce a biostimulatory e ffect in the 
target tissue. PBM  has been shown to be effective for musculoskeletal pain relief and wound healing (8), 
as well as many other applications
 (9-14). PBM  is anti -inflammatory and reduces oxidative stress, 
working primarily on the mitochondria in stressed or  ischemic tissues. The mitochondria produce nitric 
oxide (mtNO) that binds to the chromophore cytochrome c oxidase , competit ively displacing oxygen 
leading to oxidative stress and reduced ATP production. Light of suitable wavelength, sufficient 
irradiance and time when applied to injuries is absorbed by [CONTACT_9058] c oxidase , displacing mtNO  and 
thereby [CONTACT_883745]. A cascade of downstream metabolic 
effects leads to a reduction in inflammatory markers including prostaglandin E2, interleukin 1Œ≤,  
interferon ( Œ±, Œ≤, Œ≥), and tumor necrosis factor -Œ± (15-17). Anti -inflammatory and immune -modulatory 
markers are also upregulated, such as TGF -Œ≤1, IL -4, and IL -10 (18, 19). 
Lasers have a long history of use in acupuncture in lieu of needles ( 20-23). Typi[INVESTIGATOR_897] , lower doses (1 -4 
J/cm2) of laser light are used on specific points to induce a non- local or systemic effect.  Laser 
acupuncture has been shown to be effective in a variety of musculoskeletal conditions such as low back pain and knee pain, and has been shown to have significant effects on brain activation in fMRI studies
 
(24, 25) 
Cranial Lase r Refl ex Technique (CLRT)  is a novel complementary and alternative  (CAM) medicine 
intervention for musculoskeletal conditions that incorporates principles of laser acupuncture with 
chiropractic cranial reflexology (26). Developed in [ADDRESS_1236394]. Nick Wise (PI), CLRT has been incorporated 
into clinical practice by [CONTACT_883746]. It involves non- invasive laser 
stimulation of a distinct cranial microsystem discovered by [CONTACT_608879]( 27). It was  postulated that 
these cranial reflexes are similar in nature to acupuncture points and would likewise respond to 
Master Protocol CLRT for Hamstrings  Page 11 of 62 version 1.1  
January 25, 2017    
 
 photobiomodulation (PBM) from a low  level  laser  (28, 29) (30). Clinical  experience by [CONTACT_978] [INVESTIGATOR_883722] (0.5 -5 J/cm2) of laser light : the 
length, strength , and pain in a specific muscle could be improved  rapi[INVESTIGATOR_375], even in cases of chronic post -
stroke muscle spasms( 31). This pi[INVESTIGATOR_883723].  
 
 2.2: Study Rationale  
 
Preliminary Findings  
The Principal Investigator , [CONTACT_883769] , has [ADDRESS_1236395] visit  will 
include  review of inclusion/exclusion criteria and the components of the study. Those who wish to sign 
the consent will complete a brief questionnaire on their activity level, history of hamstring  injuries , and 
perceived  hamstring  tightness.  
Master Protocol CLRT for Hamstrings  Page 12 of 62 version 1.1  
January 25, 2017    
 
 Randomization /Random Allocation. Subjects who meet the inclusion criteria and give consent will be 
randomized to one of the following for the first treatment period: 1 ) active CLRT; or 2) sham laser.  At 
the first intervention visit, the research assistant will enter the subject‚Äôs assigned ID into an online 
computer program (selected by [CONTACT_316327]) to determine assignment to one of the two periods . The study biostatistician will use computer -generated random numbers to gener ate the 
allocation sequence using random blocks of random sizes.  The program documents treatment 
assignment in an un- editable form including a date stamp.  
Post Randomization. Aft er randomization, subjects will be asked to complete the three functional 
hamstring tests: KEA, HHD , and PPT . Subjects will have direct contact [CONTACT_883747].   
Assessments.  KEA : The [ADDRESS_1236396] for hamstring length ( 32) The participant 
will be  in the supi[INVESTIGATOR_435945] a treatment table . The tested extremity ( the right  leg in each  subject ) 
will be placed in a 90¬∞ hip and 90¬∞ knee position with the contralateral lowe r extremity placed flat on the 
table. A digital inclinometer will be consistently placed at the level of the medial malleoli and the 
superior pole of the patella. The examiner will maintain 90¬∞ of hip flexion. Pelvic position will be monitored by [CONTACT_883748][INVESTIGATOR_883724] a 
neutral pelvic position. The examiner will passively extend the knee to the point of a ‚Äò‚Äòstrong, but 
tolerable stretch," as reported by [CONTACT_423]. The examiner will read the angle of the inclinometer and record the mean value of three attempts. A greater angle indicates greater degree of flexibility.  
 Hand held Dynamometry ( HHD ) is currently considered a reliable and valid measurement of peak 
muscle contraction (33). The subject will be prone on the table with right  leg bent to 90¬∞. The tester will 
place the dynamometer (microFET2; Hoggan Health Industries, Salt Lake City, UT) at the hee l of the 
participant and apply  force to  the heel, gradually increasing in [ADDRESS_1236397] the force and the leg begins to move  (break 
point) . The investigator will record the mean value of three  attempts.  
 Pain Pressure Threshold ( PPT) is a reliable, accurate and valid method for measuring muscle pain 
sensitivity and response to treatment (34). The digital algometer (FDX, Wagner Instruments, Greenwich, 
CT) is a hand -held muscle tester with a range of 0 ‚Äì100 lbf that consists  of a padded disc with a diameter  
of 0.5‚Äù attached to a microprocessor -control unit that measures peak force (pounds or kilograms). The 
unit has a digital readout for peak -applied pressure and provides a built -in calibration routine that 
verifies a valid calibration. In order to determine PPT, the  researcher will  apply the tip of the algometer 
to a tender spot in the participant ‚Äôs hamstrings and increase the amount of pressure until t he 
participant verbally informs  the researcher when the sensation of pressure became pain . At this  point 
Master Protocol CLRT for Hamstrings  Page 13 of 62 version 1.1  
January 25, 2017    
 
 the algometer is removed and the peak force 
recorded. The mean of three repeated measures 
will be reported.  
 
Intervention: CLRT . Subject will don  protective 
eyewear  and remain in the prone position. The 
hamstring reflexes are two lines on the posterior 
portion of the top of the head, approximately 2 cm long and 2 cm apart, running  parallel to the sagittal 
suture  (fig. 1) . The posterior end of the reflexes 
can be located by [CONTACT_883749], or CZ point in the standardized 10 -20 EEG system, and moving 
laterally approximately 1 cm.  
Sequence :  
The aperture of the l aser probe  will be placed at 
point (a),  turned on and moved to point (b)  at a 
speed of approximately 2 c m/s. The laser will be 
turned off and quickly returned to point (a), turned on and moved to point (b) again. This will be 
repeated for a total of [ADDRESS_1236398] with the scalp during the powered laser pass, moving  aside as much hair as possible.   
Device : The treatment device to be used i n this study is a Class IIIB 810 nm 200mW near -infra red GAAlAS 
diode laser (THOR P hotomedicine Ltd, Great Britain ) that is currently marketed in the US.  The laser 
probe is FDA -cleared and classified as a non -significant risk device. The spot size is 0.[ADDRESS_1236399] -practice recommendations for laser acupuncture (35) 
recommend a dosage between 1 -4 J/cm2 per point . Since the cranial reflex point ( CRP) is a line of 2 cm , 
for the purposes of calculating dosage, we will treat it as a series of 10 connected points each with a diameter of 2mm. With the scanning rate of 2cm/s, each ‚Äúpoint‚Äù on the line will receive 1/10 of each pass , totaling 3s (out of 30s t otal) exposure time per point.  The dose per point  for this intervention is 
calculated to be approx imately 1.65 J/cm
2. 
ùëÉùëÉùëÉùëÉùëÉùëÉùëÉùëÉùëÉùëÉ  ùê∑ùê∑ùëÉùëÉùê∑ùê∑ùê∑ùê∑ùê∑ùê∑
ùê∑ùê∑ùê∑ùê∑ ÔøΩùêΩùêΩ
ùëêùëêùëêùëê2ÔøΩ=  ùëÉùëÉùê∑ùê∑ùëíùëí ùëùùëùùëÉùëÉùëÉùëÉùëÉùëÉùëÉùëÉ (ùëäùëä)‚àóùëáùëáùê∑ùê∑ùëêùëêùëÉùëÉ (ùê∑ùê∑)‚àóùëÉùëÉùê∑ùê∑ùëÉùëÉùëÉùëÉùëíùëíùê∑ùê∑ ùëôùëôùëÉùëÉùê∑ùê∑ùê∑ùê∑ ùëìùëìùëìùëìùëêùëêùê∑ùê∑
ùëÉùëÉùëÉùëÉ (1
ùëêùëêùëêùëê)
ùëìùëìùëÉùëÉùëÉùëÉùëìùëì  (ùëêùëêùëêùëê2) 
=  0.2 ùëäùëä‚àó 3ùê∑ùê∑‚àó1
0.036
4 ùëêùëêùëêùëê2= 1. [ADDRESS_1236400]‚Äôs assigned 
ID into an online computer program that will de termine assignment to one of the two treatment 
periods. Using a random number sequence to generate a permuted block of [ADDRESS_1236401] worth $[ADDRESS_1236402] 
worth $15.  
The following patient -reported variables will be assessed:  
1) Expectation of benefit : Measured with a modified Borkovec and Nau scale (36). This instrument 
provides an assessment of credibility of each intervention using an adaptation of a validated 
credibility scale previously developed fo r psychological studies for purposes of comparing th e 
two treatment arms. This instrument has been successfully adapted for use in other conditions such as chronic  pain and migraine headache . It will be administered after each subject 
completes the second visit . 
2) Perceived value of the intervention  is measur ed at the end of the active intervention via 
questionnaire.  At the end of the post -intervention phase, subjects will be invited to participate 
in a brief post -study interview to assess their overall impressions of the treatment.  
4. SELECTION AND ENROLLMENT OF PARTICIPANTS  
4.1: Inclusion Criteria  
Participants must meet all of the inclusion criteria to participate in this study . Criteria include:  
1) Between 18- 35 years of age  
2) All gender s 
3) Willing to complete two study visits over 2 -3 weeks  
4) Able to read and communicate in English  
4.2: Exclusion Criteria  
All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation . 
Exclusion criteria include:  
1) Current lower back condition with pain, numbness or tingling that radiates down the legs   
2) Active treatment for a major medical illness, such as heart disease, uncontro lled diabetes or 
hypertension, malignancy, autoimmune, or immune deficiency disorder  
Master Protocol CLRT for Hamstrings  Page 15 of 62 version 1.1  
January 25, 2017    
 
 3) History of vasculitis, intracranial mass, clotting disorder (including medication -induced, e.g., 
warfarin)  
4) Current skin malignancy on scalp  
5) Cognitive dysfunction preventing informed consent  
6) Pending or currently receiving benefits from personal injury litigation, including worker‚Äôs 
compensation  
7) Chronic long -term disability related to lumbosacral injury/symptoms  
8) Epi[INVESTIGATOR_002]  
4.3: Study Enrollment Procedures   
Sample Size and Population  
Target Population. The target population will be healthy young adults between the ages of 18 -35.  
Healthy young adults are chosen as the target population because this is a) a  pi[INVESTIGATOR_50382] b) the 
expectation of rapid subject recruitment and excellent retention.  
Recruitment Estimates . Approximately [ADDRESS_1236403] study visit.  
Consenting Process  
Informed c onsent forms (ICFs) will be reviewed with the patient by [CONTACT_883750], the 
project supervisor, or the co -investigator . The study team member will read the ICFs to the patient as 
they follow along. Any questions the patient may have  will be answered accordingly. After reviewing the 
consent, a patient may decline  to participate , sign to participate at the time of the meeting, or take the 
ICFs home with them to be signed at a later time. The patient will be considered to be a subject a t the 
time of signing the consent. Persons who cannot sign for themselves will not be recruited.  
Documentation  
Master Protocol CLRT for Hamstrings  Page [ADDRESS_1236404] 
visit using a computer -generated blocked randomization process. Please see Section 9.2 for details.   
5. STUDY INTERVENTION  
5.1: Intervention, Administration, and Duration  
CLRT is a complementary or alternative intervention that incorporates principles of laser acupuncture 
with chiropractic cranial reflexology. Instead of acupuncture points derived from TCM, CLRT involves low 
level  laser stimulation of two distinct cranial microsystems discovered by [CONTACT_608879]. The first map of 
cranial reflex points/pathways (CRP) was originally discovered by a doctor named Jack Elvidge using Applied Kinesiology, and each CRP corresponds to a major muscle or group. These soft -tissue CRPs are 
either points or directional lines on the skull, and they appear to have an influence on the particular 
muscle‚Äôs tonus and strength. It was originally found that stimulating a linear reflex with digital pressu re 
in one direction relaxed the muscle‚Äôs tone, and stimulating it in the opposite direction increased the 
tonicity.  
The second set of CRPs used in CLRT were discovered by [CONTACT_883751], D.C., and consists of points that 
relate to each vertebra of the spi[INVESTIGATOR_050], rib, sacroiliac joint, sacrum and coccyx. Denton found that subtle 
manipulations of these points affected the position and function of misaligned vertebra in manner similar to adjusting them directly. [CONTACT_883769] developed CLRT after postulating th at the CRP‚Äôs had 
similar optical properties to the acupuncture meridians, and would respond to coherent light in a similar 
manner. Upon clinical experimentation, he found that the cranial reflexes were in fact extremely 
responsive to low doses of laser lig ht. The major goal of CLRT is to quickly decrease in pain, increase 
joint range of motion, and achieve lasting functional improvements. CLRT can be performed with a range of laser power s from 5 milliwatts ( mW) to 500mW with similar results, and wavelengths from 
405nm -840nm have been used successfully.  
The first visit will last approximately 1 hour and the second visit will take 30 minutes.  
5.2: Concomitant Interventions   
5.2.1 : Allowed Interventions    
Subjects will be allowed to partake in their usual exercise and physical activities.   
Master Protocol CLRT for Hamstrings  Page 17 of 62 version 1.1  
January 25, 2017    
 
 5.2.2 : Required Interventions    
Participation in both study arms of the crossover trial .   
5.2.3: Prohibited Interventions   
None.  
5.3: Adherence Assessment  
We will define  study adherence as completion of both study visits.   
6. STUDY PROCEDURES   
6.1: Schedule of Evaluations  
Activity  Visit 1  (Week 1) Visit  2   
 (Week 2) Check -in 
Call 
(Week 3) 
People involved in visit/activity:  Study Coordinator, 
Investigator and 
Research Assistant  Investigator 
and Research 
Assistant  Research 
Assistant  
Location : Neurophysiology Lab NL Phone  
Eligibility Criteria Review  X   
Informed Consent Review   X   
Randomization  X   
Musculoskeletal History  X   
Hamstring Tightness Questionnaires  X X  
90-90 KEA  X X  
Handheld Dynamometry  X X  
Intervention  X X  
Expectation of Benefit  X   
Perceived value of the intervention   X  
Follow up    X 
6.2: Description of Evaluations   
6.2.1: Screening Evaluation  and Consenting  
Screening   
A brief telephone call by [CONTACT_883752]/exclusion criteria and 
components of the study  will be completed. If subject is interested, they will be invited to consent and 
enroll  in the study.  
Consenting  
Interested participants will travel to UNC Neurophysiology Lab at Fetzer Hall  to meet with a Study 
Coordinator or Research Assistant to review consent forms and sign and date (in a private room) .  
Master Protocol CLRT for Hamstrings  Page 18 of 62 version 1.1  
January 25, 2017    
 
 After participants sign the consent, their musculoskeletal history questionnaire  will be reviewed by [CONTACT_1600] [INVESTIGATOR_883725].  
6.2.2: Enrollment, Baseline, and/or Randomization  
Enrollment  
Subjects are enrolled at time of signing the consent form.  The analysis will be done under an 
Intention to Treat.  
Baseline Assessments  
Age, gender , hamstring injury questionnaire, perceived hamstring tightness scale, activity level .   
Randomization  
Randomization occurs at the end of the baseline and screening phase immediately prior to 
starting the intervention .    
6.2.3: Blinding  
Subjects and assess ors will be blinded to treatment allocation. The subject will be face down, eyes 
closed, and wearing protective eyewear that blocks the specific wavelength of the laser light  
during the intervention. 
Individuals authorized to break the blind include the PI [INVESTIGATOR_262053].  
Circumstances for breaking the blind include the development of a Serious Adverse Event (SAE) or 
recurrent Adverse Event (AE) apparently related to the research interventions.  
The procedure for breaking the blind is to have t he research assistant  inform the PI [INVESTIGATOR_883726].  
After each treatment session, the participants will complete a de -blinding questionnaire 
administrated by [CONTACT_883753] a dichotomous ‚Äòyes‚Äô or ‚Äòno‚Äô answer as to whether active 
treatment was received. This response will be followed by a second question regarding how 
certain they were that active treatment was received on a 0 ‚Äì10 numeric rating scale (NRS), where 
0 represents absolutely uncertain and 10 represents absolutely certain.  
6.2.4: Study  Visit s 
Study visits will ideally be  one week apart . (See Section 6.1 for Schedule of Evaluations table.)  
‚Ä¢ Visit 1:   
o Inclusion / Exclusion Criteria  
o Consenting:  Subject Enrollment   
o Study questionnaires:  Hamstring Injury questionnaire  
o Randomization  
o KEA 
Master Protocol CLRT for Hamstrings  Page [ADDRESS_1236405] PPT 
o De-blinding questionnaire  
 
‚Ä¢ Visit  2: Week [ADDRESS_1236406] PPT 
o De-blinding questionnaire  
 
6.2.5: Completion  
‚Ä¢ Study questionnaires:   
o Expectation of benefit/ Believability scale  
‚Ä¢ Evaluation for participants who discontinue study intervention early  
Potential reasons for early termination  include: subject no longer interested, adverse 
events,  subject not able or willing to follow the protocol, subject moved away from the area  
or prolonged travel .   
If subjects withdraw early, the PI [INVESTIGATOR_883727] -up by [CONTACT_883754] e vents experienced by [CONTACT_883755].  
Master Protocol CLRT for Hamstrings  Page 20 of 62 version 1.1  
January 25, 2017    
 
 7. SAFETY ASSESSMENTS  
7.1: Specification of Safety Parameters  
Low level laser devices used for the purposes of photobiomodulation or acupuncture are designated by 
[CONTACT_4760] ‚Äúnon- significant risk‚Äù devices ( 37). After four decad es of research, over 4000 pee r-reviewed 
papers  and over 150 Phase III clinical trials , there are no known side effects attached to low level laser 
therapy (LLLT). Animal studies have shown that lasering the head, or transcranial photobiomodulation 
(tcPBM ), is very safe and causes no thermal or neoplastic changes in the cortex (38). The use of tcPBM  
has been shown to have promise for treating traumatic brain injury (39-41) and stroke (42-44), as well  as 
enhancing mood( 45-47) and cognition( 48-52) in humans .  
 CLRT involves principles and laser dosages very similar to laser acupuncture. Laser acupuncture has been 
extensively studied and deemed to be safe and effective for certain musculoskeletal conditions( 21), 
especially in long -term follow up  (29). No known or anticipated serious side effects from CLRT have yet 
occurred but minor reactions may include mild delayed onset muscle soreness  or headache . Due to the 
intensity of the laser light, subjects will wear proper eye protection that blocks the specific wavelength of light while lasers are in use.  
 
Based on previous research, no serious side effects are anticipated. The PI [INVESTIGATOR_883728] I RB if any arise.  
 
Examples of safety measures include : monitoring subjects for any discomfort related to intervention; 
reports of cramps, spasms, headache or delayed onset muscle soreness.  
7.2: Methods and Timing for Assessing, Recording, and Analyzing Safety  
Parameters  
1) Timing: each  contact [CONTACT_883756].  
2) Recording: each incidence of an adverse event will be recorded in the case report form in a 
designated location for this information.  
3) Analyzing: the PI [INVESTIGATOR_883729]. 
7.3: Adverse Events  (AEs)  and Serious Adverse Events  (SAEs)  
Definition s 
An adverse event (AE) is any untoward medical occurrence in a subject during participation in the clinical 
study. An adverse event can include a sign, symptom, abnormal assessment (laboratory test value, vital signs, electrocardiogram finding, etc.), or any combination of these.  
A serious adverse event (SAE) is any AE that results in one or more of the following outcomes:  
Master Protocol CLRT for Hamstrings  Page 21 of 62 version 1.1  
January 25, 2017    
 
 ‚Ä¢ Death  
‚Ä¢ A life -threatening event  
‚Ä¢ Inpatient hospi[INVESTIGATOR_1081]  
‚Ä¢ A persistent or significant disability/incapacity  
‚Ä¢ A congenital anomaly or birth defect  
‚Ä¢ An important medical event based upon appropriate medical judgment  
Classification of AE Severity  
Classification of AEs will be based on the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4, 2009. AEs will be described by [CONTACT_105136]/diagnosis, and graded for severity (mild, moderate, or severe) , depending on the intensity of the event.  Two additional categories will be used 
based on the CTCAE system, ‚Äúlife threatening‚Äù and ‚Äúdeath‚Äù.  
Grade 1.  Mild: asymptomatic or mild symptoms; clinical or diagnostic observations only; 
minimal impact on subject‚Äôs life; intervention not indicated.  
Grade 2 . Moderate: medical care sought; significant but limited inconvenience on Activities of 
Daily Living ( ADL) or lifestyle; local or noninvasive intervention indicated.  
Grade 3. Severe: medically significant but not immediately life -threatening; disabling; limiting 
self-care; substantial disruption to the subject‚Äôs well -being; hospi[INVESTIGATOR_24599].  
Grade 4. SAE. Life -threatening consequences; urgent medical intervention indicated.  
Grade 5. SAE. Death: related to AE.  
An AE that is graded as severe (Grade 3) can be distinct from an SAE (Grades 4 and 5). A subject 
could experience a severe AE (Grade 3) that does not meet the definition of an SAE (see above). Alternatively, a subje ct could experience a moderate AE (fever, mild confusion) that meets the 
SAE definition (example - need for antibiotics to combat a life threatening infection).  
AE Attribution Scale  
AEs will also be classified on an assessment of relatedness to the study  intervention. AEs will be 
categorized according to the likelihood that they are related to the study intervention. They will be labeled as: 1) definitely related, 2) definitely unrelated, 3) probably related, or 4) possibly related to the study intervention in the opi[INVESTIGATOR_883730]. Attributions will be made by [CONTACT_978]. 
Master Protocol CLRT for Hamstrings  Page 22 of 62 version 1.1  
January 25, 2017    
 
 7.4: Reporting Procedures  
Those events that will be asked about (solicited) include: delayed onset muscle soreness and pain in the 
hamstring. Other events that could occur with maximal contraction of the hamstring strength test  
include fatigue, cramps, spasms, muscle strain , or muscle pa in.  
Unsolicited events will be captured by [CONTACT_883757].  
Time  frames for reporting and collecting AEs are weekly. Reporting of AEs must be to the IRB and OHRE. 
For SAEs the time frame is daily reporting and capture as soon as possi ble. 
Detection of AEs and SAEs will be the responsibility of  each  member of the research team  at every 
subject contact. Reporting procedures for unexpected events related to the study intervention will 
include written documentation of the finding or complaint , which  will occur within [ADDRESS_1236407] AE and  SAE data entered into a secure database.  
Reports will be distributed to the PI [INVESTIGATOR_7706] -I‚Äôs and Project Manager. These reports will be coded and 
without identifiers.  
7.5: Follow  up for Adverse Events  
Subjects who have experienced AEs will be followed until resolved or considered stable by [CONTACT_978].  For 
issues not resolved, a minimum period of follow up is [ADDRESS_1236408] on a weekly basis by 
[CONTACT_52062].  
7.6: Safety Monitoring   
The senior  advisors on this study will serve as data and safety monitors  and make up the Data and Safety 
Committee : [CONTACT_883770][INVESTIGATOR_98429], [CONTACT_105158], and [CONTACT_883771] . We will record all adverse 
events and unexpected health problems and review weekly  with the study team. Safety monitors will 
review t he adverse events and unexpected health problems after the tenth subject reaches visit 2  in the 
intervention and every 3  months thereafter.  
8. INTERVENTION DISCONTINUATION  
Discontinuation  of intervention for a participant: S ubject may stop their participation for any reason, 
e.g., the subject is non- compliant with the protocol; subject develops unacceptable side effects; or 
psychosocial circumstances prevent continuation.    
Master Protocol CLRT for Hamstrings  Page 23 of 62 version 1.1  
January 25, 2017    
 
 Possible reasons for discontinuation of the whole study :  Study closure by [CONTACT_883758] ; research 
environment is no longer supportive; multiple Unexpected Problems (UP); insufficient recruitment to 
answer research hypotheses .  If greater than 3 enrolled and randomized subjects develop a grade 3 or 
greater adverse even t due to the intervention, the entire study would be stopped and the safety 
monitors would  reevaluate.  
Early discontinuation: Participants will continue to be followed, with their permission, for another 6 
weeks if study interventions are discontinued for reasons other than the normal end of the study.  
Normal end  to the study : Subjects completing the final evaluation will be f ollowed up one week after 
the final visit  by [CONTACT_883759].  
9. STATISTICAL CONSIDERATIONS  
9.1: General Design Issues   
 
Primary Outcome  
90-[ADDRESS_1236409]  for assessing hamstring length  (53).  Results will be recorded as 
degrees of knee flexion angle. A clinically significant effect size is an increase of [ADDRESS_1236410] will be prone on the table with right leg bent to 90¬∞ and will maximally contract 
the hamstring muscle for [ADDRESS_1236411] the mean 
value of three attempts.  
 
Pain Pressure Threshold. PPT  is a reliable, accurate and valid method for measuring muscle pain 
sensitivit y and response to treatment (54). In order to determine PPT, the researcher will apply the tip of 
the algometer to a tender s pot in the participant‚Äôs hamstrings and increase the amount of pressure until 
the participant verbally informs the researcher when the sensation of pressure became pain. At this point the algometer is removed and the peak force recorded. The mean of three repeated measures will 
be reported.  An increase in PPT signifies an increase in pain tolerance.  
 
Additional Variables  
Age, gender , activity level, perceived hamstring tightness, perceived hamstring flexibility and 
perceived hamstring strength  will be assessed at baseline  and subsequent follow up visit .  
Master Protocol CLRT for Hamstrings  Page 24 of 62 version 1.1  
January 25, 2017    
 
  
9.2: Sample Size and Randomization 
 
Sample Size and Power:   Based on previously published results( 55), we would consider a mean increase 
of 5¬∫ on the KEA (e.g., from 135¬∫ to 140¬∫) to be clinically meaningful , and we assume a common 
standard deviation of 15¬∫.  We further assume that correlation between repeated measurements from 
the same individual will be at least 0.75 (likely a conservative assumption).  Under these assumptions, enrolling [ADDRESS_1236412] 80% power using a two -sided test at the 0.05 level.  
Allowing for up to 10% loss to follow -up, we will enroll 44 participants.  
9.3: Definition of Populations  
We are defining our intention- to-treat population as all subjects who are randomized. We will reta in 
randomized subjects into the treatment periods  to which they were assigned. For a per -protocol analysis  
(if necessary) , we will analyze data from subjects who attend and complete both study visits.  
9.4: Interim Analyses and Stoppi[INVESTIGATOR_883731] -specified interim analyses for any reason. The study may be suspended by 
[CONTACT_883760] [INVESTIGATOR_883732] (DSMC) if a severe adverse event occurs that is deemed to be secondary to the intervention . The DSMC may also suspend or stop the study or a study 
arm if reported adverse events are increasing, either across intervention arms or in a particular study 
arm.   
9.5: Outcomes  
Outcomes include two functional measures that will be logged into R EDCap at the time of the 
evaluation. The study coordinator will verify complete data entry after each study visit.  
9.5.1: Primary Outcome  
We define the primary outcome as the change in angle of the KEA test  from the time before 
to the intervention to afterwards .  
9.5.2: Secondary Outcomes   
We define the secondary outcome as the difference in peak hamstring strength on HHD, and difference in PPT scores  between pre and post -intervention  time periods.  
Subgroup analyses:  conduct analyses on the primary outcome stratifying on gender and 
baseline hamstring subjective tightness , flexibility and strength,  number of prior 
hamstring injuries.  
9.6: Data Analyses   
 
Master Protocol CLRT for Hamstrings  Page [ADDRESS_1236413] size along with a 95% confidence 
interval. As a secondary analysis to explore  the potential for carry -over, we will include and test a fixed 
effect for treatment- by-period interaction. If significant carry -over is identified, we will also report 
comparisons using only the period 1 data. We will use a similar approach to explore int ervention effects 
on HHD  and PPT . 
 
10. DATA COLLECTION AND QUALITY ASSURANCE  
10.1: Data Collection Forms :  Data Type & Personnel Collecting Data   
 Principal Investigator ‚ÄîNicholas Wise  
Co-Investigator - Jacob Hill  
Research Assistants ‚ÄîTBD 
 
Data Collection and Contacts with Subjects .  
Paper records collected at study visits will be entered into the REDCap database, a secure online 
research database system. Paper source documents will be locked in a file cabinet under the control of 
the full -time S tudy Coordinator.    
10.2: Data Management   
All data will be collected at the University of North Carolina at Chapel Hill . Online questionnaires will be 
completed by [CONTACT_883761] s. Data collection forms are listed in Table 5 and are attached to 
this document in appendices.  
The research assistant or investigator will  verify questionnaire completion after each study visit ; data 
will be  input by [CONTACT_60572] s. Source documents are identified by a Study Identification ( ID). 
Investigator  will compi[INVESTIGATOR_5829] a data completion report  every other month to be reviewed at study meetings.  
10.3: Quality Assurance  
10.3.1: Training  
Current HIPAA and CITI Human Ethics training certificates or their equivalents  are required of a ll 
study personnel who will be collecting, entering or managing data.  
Before participant data is collected, the PI [INVESTIGATOR_883733] 26 of 62 version 1.1  
January 25, 2017    
 
 training for applicable tasks. A log including  date s and type of training will be kept in the Study 
Regulatory Binder.  
The Study Manual of Operating P rocedures (M OP) will  include detailed procedures for each of the 
following:  
1. Consent forms  
2. Functional assessment test s (KEA, HHD, PPT)  
REDcap  will be u sed to track  recruitment data,  questionnaires, and initial and  post -intervention 
evaluations.  
The PI  [INVESTIGATOR_883734]. 
10.3.2: Quality Control Committee  
Quality control will be an agenda item of the research meeting which will include the PI,  Research 
Assistant s, and Co -Is as available.  
Data will be presented in the meeting from information gathered as described in section 10.3.3 
below.  
10.3.3: Metrics  
Outcome Measures:  
Questionnaires designed to be completed on paper ( Expectation of Benefit / C redibility survey ) will 
be collected and entered into the REDCap database by a research assistant. The r esearch assistant s, 
under supervision of the PI, will also enter study visit data, including  KEA, HHD and PPT scores . The 
research assistant  who will be responsible for data entry will not have contact [CONTACT_883762] . Double data entry for all  paper -based  outcome measures will be performed. 
Corrections will be made using source documents. If a greater than 1% discrepancy in data is found, then additional training will take place.  
10.3.4: Protocol Deviations  
Staff will be trained to record any protocol deviation that may occur while performing  their specific 
research related activities. Ma ny of the data collection forms include comment  sections where 
protocol deviation  information will be captured on the source documents. Deviations will also be 
documented in REDcap . Training of the research staff will include practices of double checking all 
demographics, inclusion/exclusion criteria, data collection procedures including capture and secure storage, intervention procedures and data management activities.   
Deviations will be documented as a writ ten report submitted to the UNC IRB by [CONTACT_978] [INVESTIGATOR_883735] 2 weeks . If warranted, c orrective action plans will be 
Master Protocol CLRT for Hamstrings  Page 27 of 62 version 1.1  
January 25, 2017    
 
 developed and submitted to the IRB as part of that reporting process.  
10.3.5: Monitoring 
Outside monitoring  of the study is not required.  However, the Regulatory binder will be maintained 
as if study monitoring were to take place.  
11. PARTICIPANT  RIGHTS AND CONFIDENTIALITY   
11.1: Institutional Review Board (IRB) Review   
This protocol and the informed consent document s and any subsequent modifications will be reviewed 
and approved by [CONTACT_883763]. The IRB application, modification , and renewal procedures will be adhered to throughout the 
study.    
11.2: Informed Consent Forms  
A signed consent form will be obtained from each participant.  
The consent form will describe the purpose of the study, the procedures to be followed, reasons not to 
be in the study, risks and benefits of pa rticipation, responsibilities of the participant, incentives and 
remunerations, privacy and confidentiality measures, and names and contact [CONTACT_71722] [INVESTIGATOR_883736].  
Procedures for obtaining and documenting informed consent: Interested persons meeting screening 
criteria  of age, inclusion / exclusion  will be given a copy of the informed consent  form  (ICF) in the 
presence of the Study Coordinator or their designee, who will then read the consent orally with the 
potential subject  (PS), indicating  important points in each section and answering any questions at that 
time. The PS will be given time to re- read any or all of the form , and they may take it home for further 
review if they so desire for signing at a later time. If they ha ve their questions answered and are willing 
to participate, the informed consent will be signed at the time of the meeting by [CONTACT_883764]. The PS is considered to be a subject in the study (enrolled) at the 
time of  the signing. A copy of the IFC will be given to each participant.  
Those below age 18, pregnant women, prisoners , and those requiring a legally authorized 
representative are excluded from participation.  
11.3: Participant Confidentiality   
Participant confidentiality  will be maintained  according to the Health Insurance  Portability and 
Accountability Act (HIPAA) .  
Any data , forms, reports, and other records that leave the site will be identified only by a participant 
Master Protocol CLRT for Hamstrings  Page 28 of 62 version 1.1  
January 25, 2017    
 
 identification number ( Participant ID, PID ) to maintain confidentiality.  
All records will be kept in a locked file cabinet  in Medical School Wing D . All computer entry and 
networking programs will be done using PI[INVESTIGATOR_34107]. I nformation will not be released without written 
permission of the participant, except as necessary for monitoring by [CONTACT_1744], the FDA, and the  OHRP . 
Research records arising from this study will be retained at a secure UNC -maintained locked site for 5 
years wi th access limited to the PI [INVESTIGATOR_883737].  
 
11.4: Study Discontinuation Understanding  
The study may be d iscontinued at any time by [CONTACT_1201], the OHRP, the FDA, or other government 
agencies as part of their duties to ensure that research participants are protected.  
12. COMMITTEES  
Data and Safety Monitoring Committee . No other committees.    
13. PUBLICATION OF RESEARCH FINDINGS  
Any presentation, abstract, or manuscript will be made available for review by [CONTACT_883765]. Publication Committee formation will be contingent on successful data collection.  
14. REFERENCES  
1. Sekir U, Arabaci R, Akova B, Kadagan SM. Acute effects of static and dynamic stretching on leg 
flexor and extensor isokinetic strength in elite women athletes. Scand J Med Sci Sports. 2010;20(2):268 -
81. doi: 10.1111/j.1600- 0838.2009.[ZIP_CODE].x. PubMed PMID: 19486475.  
2. Herbert RD, Gabriel M. Effects of stretching before and after exercising on muscle soreness and 
risk of injury: systematic review. BMJ. 2002;325(7362):468. PubMed PMID: 12202327; PMCID: 119442.  
3. Nelson AG, Kokkonen J, Arnall DA. Acute muscle stretching inhibits muscle strength endurance 
performance. J Strength Cond Res. 2005;19(2):338 -43. Epub 2005/05/21. doi: 10.1519/r -[ZIP_CODE].1. 
PubMed PMID: 15903372.  
4. Haddad M, Dridi A, Chtara M, Chaouachi A, Wong del P, Behm D, Chamari K. Static stretching  
can impair explosive performance for at least 24 hours. J Strength Cond Res. 2014;28(1):140 -6. Epub 
2013/04/26. doi: 10.1519/JSC.0b013e3182964836. PubMed PMID: 23615481.  
5. Chiarotto A, Clijsen R, Fernandez -de-las-Penas C, Barbero M. The Prevalence of Myo fascial 
Trigger Points in Spi[INVESTIGATOR_158467]: a Systematic Review and Meta -Analysis. Archives of Physical Medicine 
and Rehabilitation. doi: http://dx.doi.org/10.1016/j.apmr.2015.09.[ADDRESS_1236414] Rev. 
2007(1):CD004575. Epub 2007/01/27. doi: 10.1002/14651858.CD004575.pub2. PubMed PMID: 
17253514.  
7. Witvrouw E, Danneels L, Asselman P, D'Have T, Cambier D. Muscle flexibility as a risk factor for 
developi[INVESTIGATOR_883738]. A prospective study. Am J Sports Med. 
2003;31(1):41- 6. Epub 2003/01/18. PubMed PMID: 12531755.  
8. Chow RT, Johnson MI, Lopes -Martins RA, Bjordal JM. Efficacy of low -level laser therapy in the 
management of neck pain: a systematic review and meta -analysis of randomised placebo or active -
treatment controlled trials. Lancet. 2009;374(9705):1897- 908. Epub 2009/11/17. doi: 10.1016/s0140-
6736(09)[ZIP_CODE]- 1. PubMed PMID: 19913903.  
9. Alves AN, Fernandes KP, Deana AM, Bussadori SK, Mesquita -Ferrari RA. Effects of low -level laser 
therapy on skeletal muscle repair: a systematic review. American journal of physical medicine & 
rehabilitation / Association of Academic Physiatrists. 20 14;93(12):1073- 85. doi: 
10.1097/PHM.0000000000000158. PubMed PMID: 25122099.  
10. Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low -level laser (light) therapy (LLLT) for 
treatment of hair loss. Lasers in surgery and medicine. 2014;46(2):144 -51. doi: 1 0.1002/lsm.[ZIP_CODE]. 
PubMed PMID: 23970445; PMCID: 3944668.  
11. Dungel P, Hartinger J, Chaudary S, Slezak P, Hofmann A, Hausner T, Strassl M, Wintner E, Redl H, 
Mittermayr R. Low level light therapy by [CONTACT_883766]. Lasers in surgery and medicine. 2014;46(10):773 -80. doi: 10.1002/lsm.[ZIP_CODE]. 
PubMed PMID: 25363448.  
12. Jastifer JR, Catena F, Doty JF, Stevens F, Coughlin MJ. Low -Level Laser Therapy for the Treatment 
of Chronic Plantar Fasciit is: A Prospective Study. Foot & ankle international. 2014;35(6):566 -71. doi: 
10.1177/1071100714523275. PubMed PMID: 24510123.  
13. Sayed N, Murugavel C, Gnanam A. Management of Temporomandibular Disorders with Low 
Level Laser Therapy. Journal of maxillofacial and oral surgery. 2014;13(4):444- 50. Epub 2015/08/01. doi: 
10.1007/s12663- 013-0544- 1. PubMed PMID: 26225009; PMCID: Pmc4518790.  
14. Wang XY, Ma WJ, Liu CS, Li YX. Effect of low -level laser therapy on allergic asthma in rats. Lasers 
in medical science. 2 014;29(3):1043- 50. doi: 10.1007/s10103 -013-1456 -5. PubMed PMID: 24158722.  
15. de Almeida P, Tomazoni SS, Frigo L, de Carvalho Pde T, Vanin AA, Santos LA, Albuquerque -
Pontes GM, De Marchi T, Tairova O, Marcos RL, Lopes -Martins RA, Leal- Junior EC. What is the best 
treatment to decrease pro -inflammatory cytokine release in acute skeletal muscle injury induced by 
[CONTACT_883767]: low -level laser therapy, diclofenac, or cryotherapy? Lasers in medical science. 
2014;29(2):653- 8. doi: 10.1007/s10103 -013-1377 -3. PubM ed PMID: 23812849.  
16. Hwang MH, Shin JH, Kim KS, Yoo CM, Jo GE, Kim JH, Choi H. Low level light therapy modulates 
inflammatory mediators secreted by [CONTACT_883768]. Photochemistry and photobio logy. 2015. Epub 2015/01/06. doi: 
10.1111/php.[ZIP_CODE]. PubMed PMID: 25557915.  
17. Martins DF, Turnes BL, Cidral -Filho FJ, Bobinski F, Rosas RF, Danielski LG, Petronilho F, Santos 
ARS. Light -emitting diode therapy reduces persistent inflammatory pain: Role of  interleukin 10 and 
antioxidant enzymes. Neuroscience. 2016;324:485 -95. doi: 
http://dx.doi.org/10.1016/j.neuroscience.2016.03.035 . 
Master Protocol CLRT for Hamstrings  Page 30 of 62 version 1.1  
January 25, 2017    
 
 18. Arany PR, Nayak RS, Hallikerimath S, Limaye AM, Kale AD, Kondaiah P. Activation of latent TGF-
beta1 by [CONTACT_6398] -power laser in vitro correlates with increased TGF -beta1 levels in laser -enhanced oral 
wound healing. Wound Repair Regen. 2007;15(6):866 -74. doi: 10.1111/j.1524- 475X.2007.[ZIP_CODE].x. 
PubMed PMID: 1802 8135.  
19. Chen MH, Huang YC, Sun JS, Chao YH, Chen MH. Second messengers mediating the proliferation 
and collagen synthesis of tenocytes induced by [CONTACT_6398] -level laser irradiation. Lasers in medical science. 
2015;30(1):263- 72. doi: 10.1007/s10103- 014-1658- 5. PubMed PMID: 25231827.  
20. Al Rashoud AS, Abboud RJ, Wang W, Wigderowitz C. Efficacy of low -level laser therapy applied 
at acupuncture points in knee osteoarthritis: a randomised double -blind comparative trial. 
Physiotherapy. 2014;100(3):242- 8. doi: 10.1016 /j.physio.2013.09.007. PubMed PMID: 24418801.  
21. Baxter GD, Bleakley C, McDonough S. Clinical effectiveness of laser acupuncture: a systematic 
review. J Acupunct Meridian Stud. 2008;1(2):65 -82. doi: 10.1016/S2005- 2901(09)[ZIP_CODE] -1. PubMed 
PMID: 20633458.  
22. Elseify MY, Mohammed NH, Alsharkawy AA, Elseoudy ME. Laser acupuncture in treatment of 
childhood bronchial asthma. Journal of complementary & integrative medicine. 2013;10. Epub 
2013/07/12. doi: 10.1515/jcim -2012- 0006. PubMed PMID: 23843569.  
23. Glazov G , Yelland M, Emery J. Low -dose laser acupuncture for non- specific chronic low back 
pain: a double -blind randomised controlled trial. Acupuncture in medicine : journal of the British 
Medical Acupuncture Society. 2014;32(2):116 -23. doi: 10.1136/acupmed -2013- 010456. PubMed PMID: 
24280948; PMCID: 3995277.  
24. Siedentopf CM, Koppelstaetter F, Haala IA, Haid V, Rhomberg P, Ischebeck A, Buchberger W, 
Felber S, Schlager A, Golaszewski SM. Laser acupuncture induced specific cerebral cortical and 
subcortical activations in humans. Lasers in medical science. 2005;20(2):68 -73. doi: 10.1007/s10103-
005-0340- 3. PubMed PMID: 15990948.  
25. Quah -Smith I, Sachdev PS, Wen W, Chen X, Williams MA. The brain effects of laser acupuncture 
in healthy individuals: an FMRI investigatio n. PloS one. 2010;5(9):e12619. doi: 
10.1371/journal.pone.0012619. PubMed PMID: 20838644; PMCID: 2935390.  
26. Wise NA. Reduction Of Chronic Musculoskeletal Pain With Cranial Laser Reflex Technique 
(CLRT): A Randomized Controlled Trial Using Pressure Algomet ry. AIP Conference Proceedings. 
2010;1226(1):184- 91. doi: doi: http://dx.doi.org/10.1063/1.3453779 . 
27. Walther DS, Gavin DM, Goodheart GJ. Applied Kinesiology: Synopsis: Systems DC; 1988.  
28. Sang Min L, Chunho C, Soh K -S, Gilwon Y, editors. Measurement and analysis of optical 
properties of acupuncture points and channels. Industrial Electronics, 2001 Proceedings ISIE 2001 IEEE 
International Symposium on; 2001 2001.  
29. Law D, McDonough S, Bleakley C, Baxter GD, Tumilty S. Laser acupuncture for treating 
musculoskeletal pain: a systematic review with meta -analysis. J Acupunct Meridian Stud. 2015;8(1):2 -16. 
doi: 10.1016/j.jams.2014.06.015. PubMed PMID: 25660439.  
30. Pokorn√Ω J, Martan T, Foletti A. High Capaci ty Optical Channels for Bioinformation Transfer: 
Acupuncture Meridians. JAMS Journal of Acupuncture and Meridian Studies. 2012;5(1):34 -41. doi: 
10.1016/j.jams.2011.11.017.  
31. Wise NA. Cranial Laser Reflex Technique for post- stroke muscle spasm: a case rep ort.  North 
American Association of Laser Therapy (NAALT) Annual Conference; Tucson, AZ2007.  
Master Protocol CLRT for Hamstrings  Page [ADDRESS_1236415], Williams JD, Young CR. Concurrent validity of four clinical 
tests used to measure hamstring flexibility. J Strength Cond Res. 2008;22(2):583- 8. Epub 2008/06/14. 
doi: 10.1519/JSC.0b013e31816359f2. PubMed PMID: 18550977.  
33. Reurink G, Goudswaard GJ, Moen MH, Tol JL, Verhaar JA, Weir A. Strength Measurements in 
Acute Hamstring Injuries: Intertester Reliability and Prognostic Value of Handheld Dynamometry. The 
Journal of orthopaedic and sports physical therapy. 2016;46(8):689 -96. Epub 2016/05/14. doi: 
10.2519/jospt.2016.6363. PubMed PMID: 27170527.  
34. Ohrbach R, Gale EN. Pressure pain thresholds, clinical assessment, and differential diagnosis: 
reliability and validity in patients with myogenic pain. Pain. 1989;39(2):157 -69. Epub 1989/11/01. 
PubMed PMID: 2594394.  
35. Chow R. Dose Dilemmas in Low Level Laser Therapy: The effects of different paradigms and 
historical paradigms. LASER T HERAPY. 2001;Vol 13(Special Milennium Edition).  
36. Borkovec TD NS. Credibility of analogue therapy rationales. J Behav Therap & Exp Psychiat. 
1972;3:257- 60. 
37. FDA. FDA Compliance Guide CPG Sec. 393.200 Laser(s) as Medical Devices for Facelift, Wrinkle 
Removal, Acupuncture, Auricular Stimulation, etc.  
38. Chen CH, Wang CZ, Wang YH, Liao WT, Chen YJ, Kuo CH, Kuo HF, Hung CH. Effects of low -level 
laser therapy on M1 -related cytokine expression in monocytes via histone modification. Mediators of 
inflammation . 2014;2014:625048. doi: 10.1155/2014/625048. PubMed PMID: 24692853; PMCID: 
3945284.  
39. Lampl. Laser Treatment for Stroke.  
40. Bogdanova Y, Martin PI, Ho MD, Krengel MH, Ho VT, Yee MK, Knight JA, Hamblin M, Naeser M. 
Led therapy improves sleep and cogniti on in chronic moderate TBI: Pi[INVESTIGATOR_883739]. Archives of 
Physical Medicine and Rehabilitation. 2014;95(10):e77.  
41. Huang YY, Gupta A, Vecchio D, de Arce VJ, Huang SF, Xuan W, Hamblin MR. Transcranial low 
level laser (light) therapy for traumatic brain injury. Journal of biophotonics. 2012;5(11 -12):827 -37. doi: 
10.1002/jbio.201200077. PubMed PMID: 22807422.  
42. Hacke W, Schelinger PD, Albers GW, Bornstein NM, Dahlof BS, Kasner SE, Howard G, Shuaib A, 
Richieri SP, Dilly SG, Zivin J. Transcranial laser therapy (TLT) for acute Ischemic stroke. Results of NEST 3, 
a pi[INVESTIGATOR_883740] (RCT). Cerebrovascular Diseases. 2013;35:191.  
43. Huisa BN, Chen Y, Meyer BC, Tafreshi GM, Zivin JA. Incremental treatments with laser therapy 
augments g ood behavioral outcome in the rabbit small clot embolic stroke model. Lasers in medical 
science. 2013;28(4):1085- 9. Epub 2012/09/05. doi: 10.1007/s10103- 012-1193- 1. PubMed PMID: 
22945539; PMCID: Pmc3538923.  
44. Lapchak PA. Transcranial near -infrared laser therapy applied to promote clinical recovery in 
acute and chronic neurodegenerative diseases. Expert review of medical devices. 2012;9(1):71 -83. doi: 
10.1586/ERD.11.64. PubMed PMID: 22145842; PMCID: 3270070.  
45. Schiffer F, Johnston AL, Ravichandran C, Polcari A, Teicher MH, Webb RH, Hamblin MR. 
Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pi[INVESTIGATOR_14737] 10 patients with major depression and anxiety. Behavioral and brain functions : BBF. 
2009;5:46 . doi: 10.1186/1744 -9081 -5-46. PubMed PMID: 19995444; PMCID: 2796659.  
Master Protocol CLRT for Hamstrings  Page 32 of 62 version 1.1  
January 25, 2017    
 
 46. Rojas JC, Gonzalez -Lima F. Neurological and psychological applications of transcranial lasers and 
LEDs. Biochemical pharmacology. 2013;86(4):447 -57. doi: 10.1016/j.bcp.2013.06.012. PubMed PMID: 
23806754.  
47. Disner SG, Beevers CG, Gonzalez -Lima F. Transcranial Laser Stimulation as Neuroenhancement 
for Attention Bias Modification in Adults with Elevated Depression Symptoms. Brain stimulation. 2016. 
Epub 2016 /06/09. doi: 10.1016/j.brs.2016.05.009. PubMed PMID: 27267860.  
48. Naeser MA, Hamblin MR. Potential for transcranial laser or LED therapy to treat stroke, 
traumatic brain injury, and neurodegenerative disease. Photomedicine and laser surgery. 2011;29(7):443- 6. doi: 10.1089/pho.2011.9908. PubMed PMID: 21728786; PMCID: 3128319.  
49. Naeser MA, Saltmarche A, Krengel MH, Hamblin MR, Knight JA. Improved cognitive function 
after transcranial, light -emitting diode treatments in chronic, traumatic brain injury: two case reports. 
Photomedicine and laser surgery. 2011;29(5):351 -8. doi: 10.1089/pho.2010.2814. PubMed PMID: 
21182447; PMCID: 3104287.  
50. Naeser MA, Zafonte R, Krengel MH, Martin PI, Frazier J, Hamblin MR, Knight JA, Meehan WP, 
3rd, Baker EH. Significant imp rovements in cognitive performance post -transcranial, red/near -infrared 
light -emitting diode treatments in chronic, mild traumatic brain injury: open- protocol study. Journal of 
neurotrauma. 2014;31(11):1008- 17. doi: 10.1089/neu.2013.3244. PubMed PMID: 24568233; PMCID: 
4043367.  
51. Blanco NJ, Maddox WT, Gonzalez -Lima F. Improving executive function using transcranial 
infrared laser stimulation. Journal of Neuropsychology. 2015:n/a -n/a. doi: 10.1111/jnp.[ZIP_CODE].  
52. Gonzalez -Lima F, Barrett DW. Augmentation of cognitive brain functions with transcranial lasers. 
Frontiers in systems neuroscience. 2014;8:36. doi: 10.3389/fnsys.2014.[ZIP_CODE]. PubMed PMID: 
24672439; PMCID: 3953713.  
53. Davidson M, Keating JL. A comparison of five low back disability questionnaires: reliability and 
responsiveness. Physical therapy. 2002;82(1):8 -24. PubMed PMID: 11784274.  
54. Antonaci F, Sand T, Lucas GA. Pressure algometry in healthy subjects: inter -examiner variability. 
Scandinavian journal of rehabilitation medicine. 1998;30(1):3 -8. Ep ub 1998/04/04. PubMed PMID: 
9526748.  
55. Espejo -Ant√∫nez L, L√≥pez -Mi√±arro PA, Albornoz -Cabello M, Garrido -Ardila EM. Acute effect of 
electrical muscle elongation and static stretching in hamstring muscle extensibility. Science & Sports. 
2016;31(1):e1- e7. do i: 
http://dx.doi.org/10.1016/j.scispo.2015.05.004 . 
 
Master Protocol CLRT for Hamstrings  Page 33 of 62 version 1.1  
January 25, 2017    
 
 15. SUPPLEMENTS/APPENDICES  
Appendices  List 
A. Consent Form  
B. Data Collection Forms  
B.a  IPAQ  Activity  Questionnaire  
B.b  Hamstring History  
B.c  De-blinding Form  
B.d  Expectation of Benefit / Credibility  
     C.      AE & SAE  Forms  
 
  
 
Master Protocol CLRT for Hamstrings  Page 34 of 62 version 1.1  
January 25, 2017    
 
 Appendix A: Consent Form
Master Protocol CLRT for Hamstrings  Page 35 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 36 of 62 version 1.1  
January 25, 2017    
 
 Appendix A (cont.): Consent Form
Master Protocol CLRT for Hamstrings  Page 37 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 38 of 62 version 1.1  
January 25, 2017    
 
 Appendix A  (cont.) : Consent Form  
Master Protocol CLRT for Hamstrings  Page 39 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 40 of 62 version 1.1  
January 25, 2017    
 
  
Master Protocol CLRT for Hamstrings  Page 41 of 62 version 1.1  
January 25, 2017    
 
 Appendix A  (cont.) : Consent Form  
Master Protocol CLRT for Hamstrings  Page 42 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 43 of 62 version 1.1  
January 25, 2017    
 
  
 
 
Appendix A  (cont.) : Consent Form  
Master Protocol CLRT for Hamstrings  Page 44 of 62 version 1.1  
January 25, 2017    
 
  
 
 

Master Protocol CLRT for Hamstrings  Page 45 of 62 version 1.1  
January 25, 2017    
 
  
Appendix B (a): IPAQ (version 1.0)  
Master Protocol CLRT for Hamstrings  Page 46 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 47 of 62 version 1.1  
January 25, 2017    
 
 Appendix B(a)  cont. : IPAQ (version 1.0)  
Master Protocol CLRT for Hamstrings  Page 48 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 49 of 62 version 1.1  
January 25, 2017    
 
 
Master Protocol CLRT for Hamstrings  Page 50 of 62 version 1.1  
January 25, 2017    
 
 Appendix B(b): Hamstring History (version 1.0)  
Master Protocol CLRT for Hamstrings  Page 51 of 62 version 1.1  
January 25, 2017    
 
   

Master Protocol CLRT for Hamstrings  Page 52 of 62 version 1.1  
January 25, 2017    
 
 Appendix B.c: De -blinding Questionnaire (Ver. 0.1)
Master Protocol CLRT for Hamstrings  Page 53 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 54 of 62 version 1.1  
January 25, 2017    
 
  
Master Protocol CLRT for Hamstrings  Page 55 of 62 version 1.1  
January 25, 2017    
 
 Appendix C.a: Adverse Event Form (version 1.0)  
Master Protocol CLRT for Hamstrings  Page 56 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 57 of 62 version 1.1  
January 25, 2017    
 
  
Master Protocol CLRT for Hamstrings  Page 58 of 62 version 1.1  
January 25, 2017    
 
 Appendix C.b : Serious Adverse Event Form  (version 1.0)
Master Protocol CLRT for Hamstrings  Page 59 of 62 version 1.1  
January 25, 2017    
 
  

Master Protocol CLRT for Hamstrings  Page 60 of 62 version 1.1  
January 25, 2017    
 
 Appendix C.b (cont.): Serious Adverse Event Form (version 1.0)
 
 
 
 
  

Master Protocol CLRT for Hamstrings  Page 61 of 62 version 1.1  
January 25, 2017    
 
 Appendix C. c : Modified Borkovec and Nau Expectation of Benefit/ Credibility Form  (version 1.0)  
Master Protocol CLRT for Hamstrings  Page 62 of 62 version 1.1  
January 25, 2017    
 
  
